Table 2.

Simulation exercise format.

Agenda	Content
Proposed reassessment process	Introduce the proposed reassessment process
Case-study: bevacizumab for metastatic colorectal cancer	Clinical Evidence: RWE on overall survival and safety data
	Economic evidence: RWE on average cost per patient over time and the incremental cost-effectiveness ratio (ICER)
	Patient value evidence Patient-reported symptoms and experiences from published literature
	Implementation and Sustainability evidence RWE on budget impact
Breakout Group Discussion	Deliberate new evidence on the funded drug Issue a reassessment recommendation Critique the reassessment process
Group discussion	Debrief